AMEN FINA4.560

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2026, AMEN FINA4.560 has already paid €0.72 in dividends. The last payout was in September.

Financials

In the last quarter, AMEN FINA4.560 had revenue of €1.75bn and net profit of €217.3m

(EUR)	June 2026	YoY
Revenue	1.75bn	6.59%
Gross profit	869.2m	211.40%
Net profit	217.3m	47.20%
EBITDA	318.94m	39.23%

Fundamentals

Metric	Value
Market capitalization	€1.14bn
Number of shares	83.3m
52-week high/low	€16.25 - €13.64
Dividend yield	7.15%
Dividends TTM	€0.97
Beta	0.69
P/E ratio	13.22
PEG ratio	0.52
P/B ratio	2.61
P/S ratio	1.54

Company profile

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.